Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Progressive prostate cancer~* Medical or surgical castration with testosterone less than 50 ng/dl~* One or two prior chemotherapy regimens. At least one chemotherapy regimen must have contained docetaxel~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Adequate bone marrow, hepatic, and renal function~* Able to swallow the study drug and comply with study requirements~* Informed consent~Exclusion Criteria:~* Metastases in the brain or active epidural disease~* Another malignancy within the previous 5 years~* Clinically significant cardiovascular disease~* Gastrointestinal disorder affecting absorption

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide (Type: EXPERIMENTAL): Formerly MDV3100
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).